Diabetes

Top Story

SCALE: Liraglutide increases health-related quality of life in obesity, prediabetes

SCALE: Liraglutide increases health-related quality of life in obesity, prediabetes
October 20, 2017

Adults with obesity and prediabetes showed 3-year improvements in health-related quality of life and weight loss with once-daily subcutaneous liraglutide compared with placebo, according to findings published in Clinical Obesity.

The liraglutide 3-mg injection (Saxenda, Novo Nordisk) was approved by the FDA in 2014, and the FDA approved an updated product label earlier this year to include safety and efficacy data from this study.

In the Journals Plus

Brain glucose levels diminished in obesity, type 2 diabetes during hyperglycemia

October 20, 2017
Adults with obesity or poorly controlled type 2 diabetes have decreased intracerebral glucose levels that can lead to adverse neurocognitive consequences, according to…
In the Journals PlusPerspective

Commercial weight-management program effective for diabetes prevention

October 20, 2017
Adults at high risk for type 2 diabetes may successfully reduce that risk — and their body weight — when participating in a diabetes prevention program…
FDA News

FDA grants clearance for CGM in the surgical ICU

October 19, 2017
The FDA granted clearance to OptiScan Biomedical Corporation for its OptiScanner 5000 Glucose Monitoring System, which will allow use of the system for monitoring plasma…
More Headlines »
CME CE

Innovations in Insulin: New Opportunities to Individualize Therapy

Presented by the Annenberg Center for Health Sciences.
This activity is supported by an independent educational grant from Novo Nordisk Inc.
This activity is supported by an educational grant from Lilly.

Vivian A. Fonseca, MD, and Jonathan D. Leffert, MD, combine their expertise and discuss emerging concepts, treatment…
More »
Video
Meeting News

VIDEO: Glycemic control key to avoid CV complications in diabetes

July 14, 2017
More »
Resource Centers

CME

Practical Lipidology® Volume 4, Number 1: Focus on LDL Reduction and PCSK9 Inhibition

This activity is supported by an educational grant from Amgen

A preponderance of data shows that low-density lipoprotein cholesterol (LDL-C) plays a causal role in atherosclerotic…
More »
Advertisement
Advertisement